Split History
ETFs Holding KALA »    KALA Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators. According to our KALA split history records, Kala Pharmaceuticals has had 1 split.
KALA split history picture
Kala Pharmaceuticals (KALA) has 1 split in our KALA split history database. The split for KALA took place on October 21, 2022. This was a 1 for 50 reverse split, meaning for each 50 shares of KALA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 20 share position following the split.

When a company such as Kala Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the KALA split history from start to finish, an original position size of 1000 shares would have turned into 20 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Kala Pharmaceuticals shares, starting with a $10,000 purchase of KALA, presented on a split-history-adjusted basis factoring in the complete KALA split history. KALA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 07/21/2017
End date: 01/30/2023
Start price/share: $955.00
End price/share: $17.69
Dividends collected/share: $0.00
Total return: -98.15%
Average Annual Total Return: -51.38%
Starting investment: $10,000.00
Ending investment: $185.19
Years: 5.53
Date Ratio
10/21/20221 for 50
KALA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

KALV Split History
KBIO Split History
KIDS Split History
KOOL Split History
LCAV Split History
LCI Split History
LGND Split History
LH Split History
LIFE Split History
LJPC Split History

Also explore: KALA shares outstanding history

Email EnvelopeFree KALA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Liminal BioSciences Inc. (LMNL)
Galway Metals Inc. (GWM.CA)
Lannett Company, Inc. (LCI)
Reed's, Inc. (REED)
Phio Pharmaceuticals Corp. (PHIO)
Swvl Holdings Corp (SWVL)
Sientra, Inc. (SIEN)
Eargo, Inc. (EAR)
Alterity Therapeutics Limited (ATHE)
Aytu BioPharma, Inc. (AYTU)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

KALA Insider Buying

KALA Split History | www.SplitHistory.com | Copyright © 2013 - 2023, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.